Assessment end points for inhaled drug delivery

Area of Science:

• Pulmonary Drug Delivery and Pharmaceutics
• Biomedical Engineering and Device Development

Background:

• No single method defines the
• gold standard
• for inhaled drug delivery assessment.
• All testing levels, including in vitro, in vivo, and clinical trials, are vital for drug formulation and delivery device development.
• Sequential testing (in vitro -> in vivo -> clinical) provides a framework for optimizing inhaled therapies.

Purpose of the Study:

• To highlight the importance of a multi-level approach in inhaled drug delivery assessment.
• To emphasize the need for better integration and comparison across different testing methodologies.
• To advocate for more robust clinical trials for inhaled drug products.

Main Methods:

• Review of current methodologies for inhaled drug delivery assessment.
• Discussion of the progression from in vitro bench testing to in vivo studies and clinical trials.
• Analysis of data from scintigraphy and pharmacokinetic/pharmacodynamic studies.

Main Results:

• In vitro testing is essential for device/drug performance documentation.
• In vivo studies assess aerosol behavior in humans.
• Clinical trials remain the ultimate measure of therapeutic success, yet well-designed trials are lacking.

Conclusions:

• A comprehensive strategy integrating in vitro, in vivo, and clinical data is necessary for optimal inhaled drug delivery.
• Further research is needed to bridge testing levels and compare outcomes across methodologies.
• Well-designed, randomized controlled clinical trials are critical for comparing delivery devices and formulations, considering patient populations, dose-response, and outcomes.